QIAGEN N.V. (frankfurt prime standard:QIA) today announced that its therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) has received U.S. Food and Drug Administration (FDA) approval to guide the treatment of metastatic colorectal cancer patients with Amgen’s Vectibix® (panitumumab). This marks the third FDA approval of a companion diagnostic from QIAGEN that has been paired with a novel medicine.
QIAGEN’s growing menu of clinically validated companion diagnostics is driving global dissemination of personalized healthcare, which uses genomic information to guide treatment decisions in individual patients.
{iframe}http://www.marketwatch.com/story/qiagen-receives-fda-approval-of-therascreen-kras-rgq-pcr-kit-paired-with-second-colorectal-cancer-drug-2014-05-23{/iframe}